Satoshi Umemura ● Hisatomi Arima ● Shuji Arima ● Kei Asayama ● Yasuaki Dohi ● Yoshitaka Hirooka ● Takeshi Horio ● Satoshi Hoshide ● Shunya Ikeda ● Toshihiko Ishimitsu ● Masaaki Ito ● Sadayoshi Ito ● Yoshio Iwashima ● Hisashi Kai ● Kei Kamide ● Yoshihiko Kanno ● Naoki Kashihara ● Yuhei Kawano ● Toru Kikuchi ● Kazuo Kitamura ● Takanari Kitazono ● Katsuhiko Kohara ● Masataka Kudo ● Hiroo Kumagai ● Kiyoshi Matsumura ● Hideo Matsuura ● Katsuyuki Miura ● Masashi Mukoyama ● Satoko Nakamura ● Takayoshi Ohkubo ● Yusuke Ohya ● Takafumi Okura ● Hiromi Rakugi ● Shigeyuki Saitoh ● Hirotaka Shibata ● Tatsuo Shimosawa ● Hiromichi Suzuki ● Shori Takahashi ● Kouichi Tamura ● Hirofumi Tomiyama ● Takuya Tsuchihashi ● Shinichiro Ueda ● Yoshinari Uehara ● Hidenori Urata ● Nobuhito Hirawa

The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)

测定：FVC需要测试者尽力呼出肺内气体，这一过程约需20s，老年人或有严重肺疾病患者的体力常不堪耐受。常规的FVC测定值也会因气道阻塞者或健康高龄人的呼气时间而受影响。作者使用6s内用力呼气量(FEV6.0)代替FVC作为肺功能指标，探讨其对诊断气道阻塞和呼吸受限的优越性。

用FEV6．0代替FVC诊断气道阻塞和肺功能受限[英]／Swanney MP…∥Am J Respir Crit Care Med．

STUDY OBJECTIVES: No systematic review or meta-analysis has yet been conducted to examine the impact of the pandemic on the prevalence of sleep problems among the general population, healthcare workers, or COVID-19 patients. Therefore, this systematic review was conducted to assess the impact and prevalence of sleep problems among those categories. METHODS: APA PsycINFO; Cochrane; Cumulative Index to Nursing and Allied Health Literature (CINAHL); EBSCOhost; EMBASE; Google Scholar; MEDLINE; ProQuest Medical; ScienceDirect; Scopus; and Web of Science from 01 November 2019 to 05 July 2020. Additionally, four preprints servers (medRxiv.org; Preprints.org; psyarxiv.com; arXiv.org; biorxiv.org) were also searched for papers accepted after peer-review but not yet published and indexed. There was no language restriction. The random-effect models meta-analysis model were used with the DerSimonian and Laird methodology. RESULTS: Forty-four papers, involving a total of 54,231 participants from 13 countries, were judged relevant and contributed to the systematic review and meta-analysis of sleep problems during COVID-19. The global pooled prevalence rate of sleep problems among all populations was 35.7% [95%CI 29.4-42.4%]. COVID-19 patients appeared to be the most affected group, with a pooled rate of 74.8% [95%CI 28.7-95.6%]. Healthcare workers and the general population had comparative rates of sleep problems with rates of 36.0% [95%CI 21.1-54.2%] and 32.3% [95%CI 25.3-40.2%], respectively. CONCLUSIONS: The prevalence of sleep problems during the COVID-19 pandemic is high and approximately affect 40% of people from the general and healthcare populations. COVID-19 active patients appeared to have higher prevalence rates of sleep problems.

Sleep problems during the COVID-19 pandemic by population: a systematic review and meta-analysis.

Background:Nonadherence to medication is a recognized problem and may be the most challenging aspect of treatment.Methods:We performed a systematic review of factors that influence adherence and the consequences of nonadherence to the patient, healthcare system and society, in patients with schizophrenia. Particular attention was given to the effect of nonadherence on hospitalization rates, as a key driver of increased costs of care. A qualitative systematic literature review was conducted using a broad search strategy using disease and adherence terms. Due to the large number of abstracts identified, article selection was based on studies with larger sample sizes published after 2001. Thirty-seven full papers were included: 15 studies on drivers and 22 on consequences, of which 12 assessed the link between nonadherence and hospitalization.Results:Key drivers of nonadherence included lack of insight, medication beliefs and substance abuse. Key consequences of nonadherence included greater risk of relapse,...

https://journals.sagepub.com/doi/pdf/10.1177/2045125312474019

Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review

The symptoms of menopause can be distressing, particularly as they occur at a time when women have important roles in society, within the family and at the workplace Hormonal changes that begin during the menopausal transition affect many biological systems Accordingly, the signs and symptoms of menopause include central nervous system-related disorders; metabolic, weight, cardiovascular and musculoskeletal changes; urogenital and skin atrophy; and sexual dysfunction The physiological basis of these manifestations is emerging as complex and related, but not limited to, oestrogen deprivation Findings generated mainly from longitudinal population studies have shown that ethnic, geographical and individual factors affect symptom prevalence and severity Moreover, and of great importance to clinical practice, the latest research has highlighted how certain menopausal symptoms can be associated with the onset of other disorders and might therefore serve as predictors of future health risks in postmenopausal women The goal of this Review is to describe in a timely manner new research findings on the global prevalence and physiology of menopausal symptoms and their impact on future health

Symptoms of menopause — global prevalence, physiology and implications

Sleep plays a vital role in brain function and systemic physiology across many body systems Problems with sleep are widely prevalent and include deficits in quantity and quality of sleep; sleep problems that impact the continuity of sleep are collectively referred to as sleep disruptions Numerous factors contribute to sleep disruption, ranging from lifestyle and environmental factors to sleep disorders and other medical conditions Sleep disruptions have substantial adverse short- and long-term health consequences A literature search was conducted to provide a nonsystematic review of these health consequences (this review was designed to be nonsystematic to better focus on the topics of interest due to the myriad parameters affected by sleep) Sleep disruption is associated with increased activity of the sympathetic nervous system and hypothalamic-pituitary-adrenal axis, metabolic effects, changes in circadian rhythms, and proinflammatory responses In otherwise healthy adults, short-term consequences of sleep disruption include increased stress responsivity, somatic pain, reduced quality of life, emotional distress and mood disorders, and cognitive, memory, and performance deficits For adolescents, psychosocial health, school performance, and risk-taking behaviors are impacted by sleep disruption Behavioral problems and cognitive functioning are associated with sleep disruption in children Long-term consequences of sleep disruption in otherwise healthy individuals include hypertension, dyslipidemia, cardiovascular disease, weight-related issues, metabolic syndrome, type 2 diabetes mellitus, and colorectal cancer All-cause mortality is also increased in men with sleep disturbances For those with underlying medical conditions, sleep disruption may diminish the health-related quality of life of children and adolescents and may worsen the severity of common gastrointestinal disorders As a result of the potential consequences of sleep disruption, health care professionals should be cognizant of how managing underlying medical conditions may help to optimize sleep continuity and consider prescribing interventions that minimize sleep disruption

/pdf/short-and-long-term-health-consequences-of-sleep-disruption-13vmodjcjv.pdf

Short- and long-term health consequences of sleep disruption.

Disclosure

Funding and support was provided by AstraZeneca to MAPI Consultancy for the independent systemic review and meta-analysis of the dosing frequency and adherence in chronic psychiatric disease. Medical writing, editorial, and technical support services were provided by Goran Medic of MAPI Consultancy. Goran Medic did not receive any other form of compensation from Astra Zeneca and is fully employed by MAPI Consultancy. TD and OG are former employees of AstraZeneca. The authors report no conflicts of interest in this work.

/pdf/dosing-frequency-and-adherence-in-chronic-psychiatric-5tilgccrn9.pdf

Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis

https://pure.rug.nl/ws/files/65852639/1_s2.0_S0149291816306610_main.pdf

Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis

Background and Objective: Orphan drugs have been a highlight of discussions due to their higher prices than non-orphan drugs. There is currently no European consensus on the method of value assessment for orphan drugs. This study assessed the relationship between the prevalence of rare diseases and the annual treatment cost of orphan drugs in France, Germany, Italy, Norway, Spain, Sweden, and UK. Methods: Approved orphan drugs and prevalence data were extracted from the European Medicines Agency website. Annual treatment costs were calculated using ex-factory price. Simple regression was used to analyse the relationship between costs and prevalence. A specific bivariate analysis was performed for the rarest diseases (≤1 per 10,000). Results: 120 drugs were analysed. Prevalence ranged from 0.001 to 5 per 10,000 (mean 1.24, median 1). Annual treatment costs per patient ranged from €755 to €1,051,956 (mean €100,000, median €39,303). Results show a statistically significant inverse correlation between annual treatment cost and disease prevalence in all countries (France: r = -0.370, p = 0.002; Germany: r = -0.365, p = 0.002; Italy: r = -0.340, p = 0.002; Spain: r = -0.316, p = 0.041; UK: r = -0.358, p = 0.0004; Sweden: r = -0.414, p = 0.014; Norway: r = -0.367, p = 0.002). When analysis was focused on the rarest diseases, a stronger correlation exists in all countries (France: r = -0.525, Germany: r = -0.482, Italy: r = -0.497, Spain: r = -0.531, UK: r = -0.436, Sweden: r = -0.455, Norway: r = -0.466; all p < 0.05 except Sweden p = 0.077). Conclusions: This study shows an inverse correlation between annual treatment cost and prevalence with high statistical significance in the studied countries. Although pricing is a complex process where different attributes are assessed, this study supports the idea that payers value rarity in pricing decisions.

/pdf/do-payers-value-rarity-an-analysis-of-the-relationship-5bui746tt7.pdf

Goran Medic

Papers

Short- and long-term health consequences of sleep disruption.

Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review

Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis

Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis

Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe.